Abingdon Health Plc

Abingdon Health Plc engages in the development, manufacture, and distribution of diagnostic devices worldwide. The company offers AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test; nucleic acid lateral flow immunoassays; PCRD and PCRD FLEX, nucleic acid lateral flow tests used for rapid readouts post isothermal amplification; Abingdon Simply Test, a range of self-tests; and 2019-nCoV Antigen Test, a rapid lateral flow test for the qualitative detection of antigens to SARS-CoV-2. It also provides AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader. In addition, the company provides contract manufacturing, nucleic acid lateral flow test customization, and lateral flow development and manufacturing services. Further, it provides consultancy services to businesses in the healthcare technology sector. The company has a collaboration and co-marketing agreement with Abcam plc. Abingdon Health Plc was incorporated in 2008 and is headquartered in York, the United Kingdom.

Abingdon Health Plc trades as ABDXF on OTC. The company is classified in Healthcare / Medical - Diagnostics & Research and reports in USD.

The current profile places the business in Medical - Diagnostics & Research. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $8.43M of revenue and -$3.42M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Abingdon Health Plc can be compared against peers such as Ceapro Inc., Eiger BioPharmaceuticals, Inc., Nurosene Health Inc., Noxopharm Limited, Poxel S.A., RAMM Pharma Corp..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $32.22M, beta of 0.18, and return on equity of -64.4%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

ABDXF currently shows total debt of $1.03M and beta of 0.18. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.abingdonhealth.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.